Get the Stockscreener App
1.26
3.08%
-0.04
After Hours:
1.29
0.03
+2.38%
Gossamer Bio Inc Stock (GOSS) Latest News
You Should Read This Analysis Before Investing in Gossamer Bio Inc (NASDAQ:GOSS) - US Post News
Gossamer Bio Inc (NASDAQ: GOSS) Up 11.11% This Year: What Is Going To Happen Next - Stocks Register
Gossamer Bio regains Nasdaq compliance with bid price - Investing.com
Gossamer Bio Is A Good Speculative 'Buy' On Seralutinib For PAH And PH-ILD (NASDAQ:GOSS) - Seeking Alpha
Understanding Gossamer Bio Inc Inc. (GOSS) Price Performance Through Chart Patterns - The InvestChronicle
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
GOSS Stock Sees Surge of Approximately 15.18% in Last Five Days - Knox Daily
Gossamer Bio Inc (NASDAQ: GOSS) Stock Gained 1.83% Over A Month – Any Room To Run? - Marketing Sentinel
Gossamer Bio showcases seralutinib studies at PVRI Congress - MSN
Insider Alert: Gossamer Bio Awards Massive Stock Options Package Worth $586,500 - StockTitan
Are Smart Investors Making the Right Decision? Gossamer Bio Inc (GOSS) - SETE News
Gossamer Bio Inc (GOSS) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Octagon Capital Advisors LP Increases Stake in Gossamer Bio Inc - GuruFocus.com
Real-Time Update: Gossamer Bio Inc (GOSS) Stock Navigates the Market with Up-to-Date Data - The News Heater
Investor’s Delight: Gossamer Bio Inc (GOSS) Closes Weak at 1.02, Down -0.97 - The Dwinnex
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive
Gossamer Bio (NASDAQ:GOSS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Analysts Offer Predictions for Gossamer Bio FY2029 Earnings - MarketBeat
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress - Business Wire
Gossamer Bio’s (GOSS) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Weighs in on Gossamer Bio FY2029 Earnings - Defense World
Vanguard Group Inc Reduces Stake in Gossamer Bio Inc - GuruFocus.com
Gossamer Bio And 2 Other Promising Penny Stocks On US Exchanges - Simply Wall St
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress - Business Wire
Game-Changing PAH Treatment Combo Shows Powerful Synergistic Effects in Latest Clinical Data - StockTitan
Cantor Fitzgerald Estimates Gossamer Bio FY2025 Earnings - Defense World
Brokers Set Expectations for Gossamer Bio FY2025 Earnings - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 12.8% in December - MarketBeat
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight - GlobeNewswire Inc.
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by Geode Capital Management LLC - Defense World
Why Gossamer Bio, Inc. (GOSS) Is Among the Best Penny Stocks to Invest In According to Media? - Yahoo Finance
Gossamer Bio Grants 225,000 Stock Options to New Employees in Retention Push - StockTitan
12 Best Penny Stocks to Invest in According to the Media - Insider Monkey
3 US Penny Stocks With Market Caps Over $100M - Simply Wall St
Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Large Increase in Short Interest - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Up 10.0% in December - Defense World
Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know - MSN
The Manufacturers Life Insurance Company Boosts Stock Position in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Biggest stock gainers and losers on Thursday - The Africa Logistics
US Penny Stocks: 3 Picks With Market Caps Under $200M - Simply Wall St
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio - The Manila Times
XOMA Royalty Acquires Pulmokine for $20 Million Adding the - GlobeNewswire
XOMA Royalty Acquires Pulmokine for $20M, Adds Phase 3 PAH Drug to Portfolio - StockTitan
Gossamer Bio: Q3 Earnings Snapshot - Marketscreener.com
Adicet Bio Inc (NASDAQ: ACET) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
GSA Capital Partners LLP Invests $67,000 in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Gossamer Bio Inc (GOSS)Monday, Aug 26, 2024 - Smartkarma
All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy - MSN
US Bancorp DE Makes New $39,000 Investment in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) - Yahoo Finance
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):